UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $55.
UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $55.